AI Article Synopsis
- The study investigates the effects of primary tumor (PT) on the immune activity and metastatic status of sentinel lymph nodes (SLNs) in melanoma patients.
- It finds that SLNs removed shortly after PT (IM-SLNs) show a higher incidence of micrometastases and lower immune activity compared to those removed later (DEL-SLNs).
- Higher immune activity and the presence of specific immune cells in DEL-SLNs suggest that the timing of SLN removal influences prognosis, with DEL-SLNs indicating a worse outcome due to the melanoma's ability to evade immune responses.
Article Abstract
Background: Presence of micrometastases in the sentinel lymph node (SLN) is currently used to assess prognosis of melanoma patients. The immunoactivity within the SLN is known to be influenced by the primary tumor (PT), which may in turn impact the SLNs' metastatic state.
Aim: We characterize the temporal dependence and underlying mechanisms of the immunological effects of the PT on the SLN.
Methods: The prognostic value of SLN state as a function of PT removal time was evaluated. To put the results into a functional context, selected PTs and corresponding SLNs were analyzed for gene and protein expression patterns.
Results: In a cohort of 202 patients with known distant metastasis and similar PT prognostic characteristics, SLNs removed before or within one week after the PT (IM-SLN) had a higher incidence of micrometastases than those removed at least one week after the PT (DEL-SLN). The immunoactivity in IM-SLN was found to be lower than in DEL-SLN. Specifically, in IM-SLNs, T helper 17 / regulatory T-cells were predominant, whereas in DEL-SLNs, cytotoxic γδT-cells were more frequent. The higher immune activity in DEL-SLNs was probably facilitated by CD209 antigen-presenting cells. Indeed, in PT with high TGFβ expression CD209 cells appear to be trapped and no increased immunoactivity was observed in DEL-SLN.
Conclusions: Presence of micrometastases in DEL-SLNs have a higher negative prognostic value as in IM-SLNs since they indicate not only a melanoma's propensity to metastasize, but possibly also its capacity to escape immune responses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2024.115054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carcinosarcoma of the breast: Facing the challenge of a rare nosologic entity.
World J Clin Cases
January 2025
Department of Surgery, National and Kapodistrian University of Athens, Athens 11527, Greece.
Carcinosarcoma (CS), also known as metaplastic breast carcinoma with mesenchymal differentiation, is one of the five distinct subtypes of metaplastic breast cancer. It is considered as a mixed, biphasic neoplasm consisting of a carcinomatous component combined with a malignant nonepithelial element of mesenchymal origin without an intermediate transition zone. Although cellular origin of this neoplasm remains controversial, most researchers declare that neoplastic cells derive from a cellular structure with potential biphasic differentiation.
View Article and Find Full Text PDFASO Author Reflections: Sentinel Lymph Node Biopsy for Patients with a Non-classic Lobular Carcinoma In Situ Breast Biopsy.
Ann Surg Oncol
January 2025
Department of Surgery, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
[Evidence for the extent and oncological benefit of lymphadenectomy for esophageal cancer].
Chirurgie (Heidelb)
January 2025
Klinik und Poliklinik für Allgemein‑, Viszeral‑, Thorax- und Transplantationschirurgie, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
The prognosis for esophageal cancer is determined in particular by the depth of infiltration (T stage) and lymph node metastasis (N status). In patients with locally advanced tumors, surgical resection is the current standard. The extent of the lymphadenectomy depends on the localization of the tumor, analogous to the choice of surgical technique.
View Article and Find Full Text PDFSingle-Injection Composite Tracer Achieves Intraoperative Dual-Tracing and Precise Localization of Sentinel Lymph Nodes.
ACS Appl Mater Interfaces
January 2025
Sixth People's Hospital, School of Medicine & School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, P. R. China.
The use of dual-tracer contrast agents in clinical applications, such as sentinel lymph node (SLN) identification, offers significant advantages including enhanced accuracy, sensitivity, as well as comprehensive and multimodal visualization. In the current clinical practice, SLNs are typically marked prior to surgical resection by multiple and sequential injections of two tracers, the radioactive tracer and methylene blue (MB) dye. This imposes physical and psychological burden on patients and medical staff.
View Article and Find Full Text PDFSentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after neoadjuvant chemotherapy.
Breast Cancer Res Treat
January 2025
Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland.
Purpose: The purpose of this study was to evaluate the feasibility and safety of indocyanine green (ICG) fluorescence as an alternative to traditional sentinel lymph node biopsy (SLNB) techniques in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC). Specifically, the study aimed to assess sentinel node identification rates and the effectiveness of ICG in axillary staging without the use of radioactive tracers.
Methods: This retrospective study included 71 BC patients treated with NAC, who underwent SLNB using ICG fluorescence between 2020 and 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!